Table 3.
Comparison of demographic data in patients in groups E and non-E
| Item | Group E (n = 142) | Group non-E (n = 229) | p value |
|---|---|---|---|
| Age (years) | 41.7 ± 16.6 | 55.0 ± 18.0 | < 0.01 |
| Gender (female) | 42 (30%) | 70 (31%) | 0.839 |
| Body mass index (kg/m2) | 23.3 | 22.7 | 0.421 |
| Intervertebral disc level | |||
| L1/2 | 3 (3%) | 5 (2%) | 0.963 |
| L2/3 | 5 (3%) | 10 (4%) | 0.687 |
| L3/4 | 6 (4%) | 13 (6%) | 0.537 |
| L4/5 | 72 (51%) | 113 (49%) | 0.799 |
| L5/S1 | 54 (38%) | 90 (39%) | 0.806 |
| Symptom duration before injection (months) | 5.3 [1–13] | 8.2 [1–22] | 0.027 |
| Baseline Pfirrmann criteria | |||
| Grade II | 10 (7%) | 5 (2%) | 0.021 |
| Grade III | 79 (56%) | 102 (44%) | 0.038 |
| Grade IV | 46 (33%) | 111 (48%) | < 0.01 |
| Grade V | 7 (5%) | 11 (5%) | 0.956 |
| Classification of herniation | |||
| Subligamentous | 96 (68%) | 138 (60%) | 0.154 |
| Transligamentous | 46 (32%) | 91 (40%) | 0.154 |
| High-intensity MRI signal in herniation | 42 (30%) | 28 (13%) | < 0.01 |
| Injection into central region of disc | 134 (94%) | 207 (90%) | 0.172 |
| Baseline VAS leg pain | 6.9 ± 1.8 | 7.3 ± 1.7 | 0.358 |
| Bulging ratio of herniation (%) | 30.2 ± 10.9 | 28.4 ± 11.2 | 0.137 |
| Reduction rate of herniated mass volume (%) | 38.2 ± 19.2 | 26.8 ± 14.2 | 0.024 |
| ≥ 50% decrease of herniated mass volume (n) | 45 (31%) | 51 (22%) | 0.044 |
Continuous data are presented as mean ± standard deviation